Interactions médicamenteuses
Dipyridamole + Regadenoson
Gravité: Majeure
Dipyridamole and Regadenoson: major interaction.
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
Résumé
Dipyridamole inhibits cellular adenosine uptake and deamination, which can potentiate adenosine receptor-mediated effects and alter the response to the A2A agonist regadenoson during myocardial perfusion imaging. The result may be unpredictable vasodilation, hypotension or altered test performance.
Ce que signifie cette interaction, en termes simples
Dipyridamole and Regadenoson can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Dipyridamole belongs to Cardiovascular; Regadenoson belongs to Cardiovascular.
Pourquoi elle survient
Dipyridamole raises adenosine levels and alters adenosine receptor signaling, so the pharmacodynamic response to regadenoson is unpredictable.
Conduite à tenir
Withhold dipyridamole for at least 2 days before regadenoson stress testing, as recommended in labeling. Monitor blood pressure and ECG during the procedure if exposure cannot be avoided.
Questions à poser à votre pharmacien
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour débloquer les conseils complets de prise en charge pour Dipyridamole et Regadenoson, les notes complémentaires, le détail des données probantes et le vérificateur d'interactions pour une ordonnance complète.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Essayez Pro+ gratuitement pendant 7 jours sur le web. Sans carte.
Autres interactions de Dipyridamole
- Dipyridamole + Riociguat Contre-indiquée
- Adenosine + Dipyridamole Majeure
- Betrixaban + Dipyridamole Majeure
- Dabigatran + Dipyridamole Majeure
- Dipyridamole + Venetoclax Majeure
- Dipyridamole + Vorapaxar Majeure
Autres interactions de Regadenoson
- Regadenoson + Theophylline Majeure
- Caffeine + Regadenoson Modérée
Questions fréquentes
Can I take Dipyridamole with Regadenoson?
MediHelp rates the interaction as major. Dipyridamole and Regadenoson can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Dipyridamole inhibits cellular adenosine uptake and deamination, which can potentiate adenosine receptor-mediated effects and alter the response to the A2A agonist regadenoson during myocardial perfusion imaging. The result may be unpredictable vasodilation, hypotension or altered test performance.
How serious is the interaction between Dipyridamole and Regadenoson?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Withhold dipyridamole for at least 2 days before regadenoson stress testing, as recommended in labeling. Monitor blood pressure and ECG during the procedure if exposure cannot be avoided.
What other medicines interact with Dipyridamole?
MediHelp also lists interactions of Dipyridamole with, for example, Riociguat, Adenosine, Betrixaban. The full list is on the Dipyridamole page.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
